Skip to main content

Advertisement

Table 1 Antifungals resistance of Candida isolates from HC or RTT patients

From: Intestinal Candida parapsilosis isolates from Rett syndrome subjects bear potential virulent traits and capacity to persist within the host

Species Antifungals Healthy controls (HC) Rett syndrome (RTT) subjects
MIC (μg/ml) aCBPs MIC (μg/ml) aCBPs
MIC50 MIC90 %S %R MIC50 MIC90 %S %R
C. albicans Fluconazole 0.5 > 64 75.6 24.4 1 2 75 25
Itraconazole 0.25 > 8 36.6 63.4 0.0156 0.0156 100 0
5-Flucytosine 0.125 0.5 97.6 2.4 0.125 0.125 100 0
C. parapsilosis Fluconazole 0.5 2 92.9 7.1 2 > 64 64.3 35.7
Itraconazole 0.0156 0.125 100 0 0.0156 > 8 64.3 35.7
5-Flucytosine 0.125 0.5 100 0 0.125 0.125 100 0
b Candida spp. Fluconazole 0.125 0.25 100 0 > 64 > 64 0 100
Itraconazole 0.0156 0.0156 100 0 8 8 0 100
5-Flucytosine 0.125 0.125 100 0 0.125 0.125 100 0
  1. aAccording to EUCAST recommendations; S sensible; R Resistant; MIC ranges: Fluconazole 0.125–64 μg/ml; Itraconazole 0.0156–8 μg/ml; 5-Flucytosine 0.125–64 μg/ml. bCandida spp. isolated from RTT subjects (i.e. C. glabrata, C. pararugosa and C. tropicalis); Candida spp. isolated from HC (i.e. C. deformans, C. intermedia and C. lusitaniae)